The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of multiple myeloma patients

Salomon-Perzyński, Aleksander; Bluszcz, A; Krzywdzińska, Agnieszka; Spyra-Górny, Zofia; Jakacka, Natalia; Barankiewicz, Joanna; Borg, Katarzyna; Solarska, Iwona; Szpila, Tomasz; Puła, Bartosz; Grosicki, Sebastian; Jamroziak, Krzysztof

doi:10.20452/pamw.15316

Cited by 5 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further explore the added predictive value of cytogenetic variables, subsets with FISH-defined chromosome abnormalities and GEP were extracted. We conducted an assessment of the prognostic significance of various chromosomal aberrations, including deletion (17p del) [ 30 ], gain (1q gain) [ 31 ], and translocation (4;14, 14;16) [ 32 ], as well as gene expression profile (GEP) scores within specific cytogenetic subsets ( Supplemental Tables S8–S11 ). The incorporation of these genetic signatures demonstrated an enhancement in the c-index, indicating improved prognostic accuracy.…”

Section: Resultsmentioning

confidence: 99%

A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation

Guo,

Strouse,

Mery

et al. 2024

Cancers

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) has been a mainstay in myeloma treatment for over three decades, but patient prognosis post-ASCT varies significantly. In a retrospective study of 5259 patients with multiple myeloma (MM) at the University of Arkansas for Medical Sciences undergoing ASCT with a median 57-month follow-up, we divided the dataset into training (70%) and validation (30%) subsets. Employing univariable and multivariable Cox analyses, we systematically assessed 29 clinical variables, identifying crucial adverse prognostic factors, such as extended duration between MM diagnosis and ASCT, elevated serum ferritin, and reduced transferrin levels. These factors could enhance existing prognostic models. Additionally, we pinpointed significant poor prognosis markers like high serum calcium and low platelet counts, though they are applicable to a smaller patient population. Utilizing seven easily accessible high-risk variables, we devised a four-stage system (ATM4S) with primary stage borders determined through K-adaptive partitioning. This staging system underwent validation in both the training dataset and an independent cohort of 514 ASCT-treated MM patients from the University of Iowa. We also explored cytogenetic risk factors within this staging system, emphasizing its potential clinical utility for refining prognostic assessments and guiding personalized treatment approaches.

show abstract

Section: Resultsmentioning

confidence: 99%

A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation

Guo,

Strouse,

Mery

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…However, in this study, there was no difference in IgH rearrangement between the RI and no-RI groups. The incidence of RI with positive chromosome 17 deletion detected during MM treatment has been reported to be higher in the RI group compared to the no-RI group, which were 12.5% and 6.9,% respectively ( 18 ). However, in this study, there was no difference between the RI and no-RI groups.…”

Section: Discussionmentioning

confidence: 98%

Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients

Gao

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveIgD multiple myeloma (MM) is a rare type of MM, accounting for about 1%–2% of all MMs. IgD MM always causes kidney damage and even leads to renal failure, which is the most common complication. This study aimed to explore the risk factors of renal damage and prognosis of IgD MM patients.DesignFrom March 2018 to November 2021, 85 patients with IgD MM diagnosed for the first time at the First Affiliated Hospital of Zhengzhou University were included in this study. We collected information on clinical features and laboratory examinations. Patients were divided into the renal impairment (RI) (47/85) and non-renal impairment (no-RI) (38/85) groups. Binary logistic regression was used to explore risk factors of renal damage. The Chi-square test was used to analyze the difference in chemotherapy effect between the two groups. We also analyzed whether early dialysis was beneficial to acute renal failure (RF) in IgD MM patients. Finally, Kaplan-Meier was used to compare the survival of the two groups.ResultsIn IgD MM, 55.3% of patients had renal damage as a complication, of which up to 59.6% presented with acute renal failure as the first manifestation. Serum β2-microglobulin (β2-MG) was an independent risk factor for renal damage in IgD MM (p = 0.002), but cytogenetic analysis suggested that it had no effect on patients’ renal damage. There was also no significant difference in the effect of chemotherapy between the two groups (p = 0.255). In patients with acute renal failure, there was no significant difference between dialysis and no dialysis groups in the proportion of patients with improved renal function after treatment. The median overall survival (OS) of the RI group was significantly shorter than that of the no-RI group (p = 0.042). In the RI group, the median OS was 29 months, and in the no-RI group, the median OS was > 40 months.ConclusionElevated serum β2-MG is an independent risk factor for renal damage. Compared with the no-RI group, patients in the RI group had poorer prognosis and shorter median OS. For patients with acute renal failure as the first manifestation, the treatment of primary disease is more meaningful than dialysis.

show abstract

“…We and others have previously shown that the evolution of cytogenetic aberrations over time has prognostic significance in MM [ 51 , 52 , 53 ]. Recently, Yan et al performed a single-cell analysis using quantitative multi-gene FISH on 129 longitudinally sampled specimens from 57 MM patients confirming that patients with stable cytogenetic structure achieve significantly longer survival than patients with evolutionary dynamics [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing

et al. 2022

Self Cite

View full text Add to dashboard Cite

Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four different patterns of mutation evolution were found: branching-, mutation acquisition-, mutation loss- and a stable mutational pathway. Better response to anti-myeloma therapy was more frequently observed in patients who followed the mutation loss—compared to the mutation acquisition pathway. More than two-thirds of patients had druggable genes mutated (including cases of heavily pre-treated disease). Only 7% of patients had a stable copy number variants profile. Consequently, a redistribution in stages according to R-ISS between the first and paired samples (R-ISS″) was seen. The higher the R-ISS″, the higher the risk of MM progression and death. We provided new insights into the genetics of MM evolution, especially in heavily pre-treated patients. Additionally, we confirmed that redefining R-ISS at MM relapse is of high clinical value.

show abstract

The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of multiple myeloma patients

Cited by 5 publications

References 21 publications

A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation

A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation

Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients

Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing

Contact Info

Product

Resources

About